热休克蛋白-抗原肽复合物疫苗预防肝癌术后复发32例  

HSP-peptide complex vaccine in preventing postoperative recurrence of hepatocarcinoma: 32 cases report

作　　者：赵子粼[1] 鄢莉[1] 崔建东[1] 师建国[2] 龙桂宁[1] 

机构地区：[1]解放军第303医院肿瘤科,广西南宁530021 [2]第四军医大学肿瘤研究所,陕西西安710033

出　　处：《第四军医大学学报》2005年第22期2076-2078,共3页Journal of the Fourth Military Medical University

摘　　要：目的:探讨热休克蛋白-抗原肽复合物(HSP)疫苗预防肝癌术后复发的效果.方法:回顾性分析32例应用HSP疫苗的原发性肝癌患者,并检测治疗前后T细胞亚群、NK细胞活性和血清IL-2受体水平的变化,计算3 a内的生存率,并与对照组比较.结果:治疗组术后3 mo CD3+,CD8+,CD4+/CD8+水平与术前和对照组比较有显著性差异(P<0.05),NK细胞活性较治疗前明显升高(P<0.01);治疗组3a生存率为68.8%,与对照组37.5%比较明显升高(P<0.05).结论:肝癌术后应用HSP疫苗能明显提高患者免疫功能,且可预防术后复发、提高远期生存率.AIM： To investigate the effects of heat shock protein-peptide complex as anti-tumor vaccines in preventing the postoperative recurrence of primary liver cancer （PLC）. METHODS： The cases reviewed were 32 cases of hepatocarcinoma treated post operatively with HSP-peptide complex vaccine. The CD3^＋, CD8^＋, CD4^＋/CD8^＋, NK activity and the levels of serum SIL-2R were tested before and after treatment and 1-, 2- and 3-year survival rates were analyzed. RESULTS： CD3^＋ , CD8^＋ and the activity of NK cells increased and CD4^＋/CD8^＋ decreased significantly compared with those of controls （ P 〈 0.05 ）. The 3-year survival rate was 68.8% in the treatment group compared with 37.5% in controls （ P 〈0.05）. CONCLUSION： HSPpeptide complex vaccine may improve immunity and prevent postoperative recurrence of PLC and prolong patients＇ survival time.

关 键 词：癌 肝细胞 复发 热休克蛋白-抗原肽复合物 肿瘤疫苗 

分 类 号：R735.7[医药卫生—肿瘤]